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Summary We synthesized recombinant Echinococcus granulosus protoscolex recP29 antigen
to be preliminarily assessed by ELISA and immunoblotting. RecP29-serology was carried out
on 54 young patients with cystic echinococcosis (CE). Patients were classiﬁed into either cured
(CCE) (n = 40) or non-cured (NCCE) (n = 14) CE patients. RecP29 ELISA showed a gradual decrease
of antibody concentrations in all CCE cases that were initially (before treatment) seropos-
itive to this antigen (25 out of 40) or that seroconverted following treatment. A complete
seronegativity was reached within 3 years post-surgery in all of these cases. Conventional
HCF ELISA yielded seronegativity in only 10% of initially recP29-seropositive CCE patients
(P = 0.086). Likewise, recP29 immunoblotting yielded seronegativity in 93% of 29 out of 40 ini-
tially recP29-immunoblot-positive CCE patients after 3 years follow-up, compared with 72% in
the HCF immunoblotting (P = 0.060). Eleven out of 14 NCCE patients were initially positive by
recP29 ELISA, and 10 out of these maintained a marked anti-recP29 antibody reactivity until
the endpoint of the follow-up period. All 14 NCCE cases were initially seropositive by recP29
immunoblotting, and 13 cases remained seropositive until the end of the study. Thus, recombi-
nant P29 protein appears prognostically useful for monitoring those post-surgical CE cases with
an initial seropositivity to this marker.
© 2008 Royal Society of Tropical Medicine and Hygiene. Published by Elsevier Ltd. All rights
reserved.
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. Introduction
ne of the particular features characterizing the follow-
p period of treated cases of cystic echinococcosis (CE)
s recurrence or relapse after treatment, e.g. as a conse-
uence of non-radical surgical procedures or peri-surgical
pillage of parasite material, especially protoscoleces.1
onsequently, an appropriate strategy and methodology is
andatory in follow-up of CE cases, especially in view
o reliably evaluating the success or failure of therapy,
nd detecting newly growing or relapsing cysts as early
s possible. In this respect, imaging techniques such as
-ray, ultrasonography (US), computed tomography (CT)
nd magnetic resonance imaging (MRI) are very useful,
lthough sometimes a concise discrimination between inac-
ivated/dead or still viable cysts cannot be provided
ith these techniques.2 Immunodiagnosis has been used
any times to support clinical follow-up of CE patients
fter surgical or pharmacological treatment,3—8 but the
esearchers of most of these studies agreed that an
mprovement of the serological tools may be of great bene-
t.
So far, predominantly crude antigens have been used as
he main antigen source for carrying out primary serodiag-
osis and also serological follow-up studies on patients after
urgical or pharmacological treatment.9 Post-treatment
onitoring of CE patients with such antigens has been of
nly limited help in prognostically classifying the status
f a CE patient after treatment, and serological results
llowed the discrimination of cured and non-cured sta-
us of CE only retrospectively. This could be due to the
emporally delayed reaction of antibody concentrations
o clinical changes,10 in addition to the persistence of
peciﬁc antibodies for several years after recovery.1,11,12
mportantly, this made it difﬁcult to predict early enough
he outcome of surgery. Therefore, new markers that
llow the prognostic assessment of post-operative develop-
ent of disease are highly demanded. Considerable efforts
ave recently been undertaken to develop recombinant
roteins with potential usefulness in serodiagnosis. Thus,
everal recombinant antigens have been expressed and
erologically evaluated, including the two different AgB
ubunits EgAgB1 and EgAgB2,13,14 and recombinant Ag5,15
ecEpC116 and recEgCMDH (cytosolic malate dehydrogenase
omologue).17 Most of these studies preliminarily docu-
ented a high diagnostic performance of the recombinant
ntigens.9,14—16,18,19 Alternatively, synthetic peptides includ-
ng p176,20,21 derived from the antigen B sequence, and
he 89—122, which mimics an epitope of Ag5,22 also pro-
ided interesting ﬁndings. Unfortunately, these recombinant
ntigens and synthetic peptides were not (or only poorly)
nvestigated for their prognostic value in the serological
ollow-up of CE.
We recently reported an interesting double band of
7—28 kDa, which remained persistently recognized by
ctive or non-cured CE (NCCE).23 Conversely, cured CE
atients (CCE) progressively lost their antibody levels to this
7—28 kDa double band.23
The objective of the present study was to clone and
xpress the gene(s) encoding for this/these proteins and to
rovide a preliminary assessment of the serological follow-
p value of this antigenic tool.
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. Materials and methods
.1. Antigens, MS-MS and database search
rotoscolex soluble protein extract (PSSA) was obtained and
rocessed as previously described.23 Proteins (10g/cm gel
lot) were subsequently separated on a 5—20% linear gra-
ient polyacrylamide gel as described by Gottstein et al.24
roteins were visualized using a silver stain protocol spe-
iﬁc for mass spectrometry as described by Shevchenko et
l.25 Protein bands of interest were excised from the SDS-
olyacrylamide gel, and subjected to proteomic analysis
t Core Facility Proteomics, Centre Medical Universitaire,
eneva University, Switzerland. Brieﬂy, bands were sub-
ected to in-gel trypsin digestion. The obtained fragments
ere separated and analyzed by liquid chromatography
LC) coupled to an electrospray mass spectrometer (LC-
SI-MS/MS). The resulting spectra were searched against
he National Center for Biotechnology Information non-
edundant and expressed sequence tag (EST) databases by
sing the MASCOT search engine (MATRIX Science, Lon-
on, UK). MS data were extracted using the Mascot script
ithin Analyst QS (http://www.matrixscience.com) and the
atabases were searched in the tandem MS (MS/MS) ion
ode. Hits to a number of contiguous overlapping ESTs
ere obtained, and these were aligned to obtain the ﬁnal
equence. The deduced amino acid sequence was investi-
ated for potential phosphorylation and glycosylation sites
y using the following ExPASy proteomics servers: NetPhos,
etNGlyc, NetOGlyc and Yin OYang (http://www.expasy.ch).
n addition, sequence homology search (quick Blast P engine
t ExPASy proteomics server and MultAlin at the Insti-
ut National de Recherche Agronomique, Paris, France),
-terminal signal peptide analysis (Signal P 3.0 pro-
ram; http://www.expasy.ch) and identiﬁcation of speciﬁc
omain (SMART: simple modular architecture research tool
t EMBL, Heidelberg, Germany; http://www.smart.embl-
eidelberg.de/smart/show motifs) were also performed.
.2. Parasite RNA extraction and RT-PCR
otal RNA was prepared from E. granulosus protoscoleces
G1 strain) freshly isolated from a sheep hydatid cyst using
he RNeasy Mini Kit 50 (QIAGEN, Basel, Switzerland; cat.
o. 74104) according to the manufacturer’s instructions.
DNA synthesis was performed using Omniscript Reverse
ranscriptase (QIAGEN; cat. no. 205111). Brieﬂy, cDNA was
ynthesized with total RNA at a ﬁnal reaction volume
f 20l containing 2l of 10× buffer RT, 0.5mmol/l of
ach dNTP, 1mol/l of Random primers (Promega, Dueben-
orf, Switzerland), 10U RNase inhibitor and 4U Omniscript
everse Transcriptase. Following incubation for 1 h at 37 ◦C,
mniscript Reverse Transcriptase was inactivated by heating
he mixture to 93 ◦C for 5min..3. PCR and cloning
ynthesized cDNA used for the production of the recombi-
ant protein was ampliﬁed using speciﬁc primers designed
rom published nucleotide sequences (see Table 1). CACC
Recombinant Echinococcus granulosus P29 serology
Table 1 Primer pairs used for ampliﬁcation of P29 gene
sequencesa.
Forward 1 (F1): 5′-CACCTCCGGATTTGACGTTACTAAG-3′
Forward 2 (F2): 5′-CACCACCGACAAACTGGGTACTGC-3′
Reverse (R): 5′-CTACTCGCCCAGCATCATCATACT-3′
a These primers were designed based on nucleotide sequence
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inactive for the whole study period with regard to clini-information available in GenBank (accession no. AF078931).
Primers were synthesized by MWG Biotechnologies, Basel,
Switzerland.
nucleotides were added to the 5′ end of the forward primer
to facilitate cloning of PCR products. PCR ampliﬁcation was
performed in a 50l reaction mixture containing 1× PCR
buffer (2mmol/l MgSO4), 0.2mmol/l dNTP mix, 1 pmole
of each primer and 1.5U pfu DNA polymerase. Samples
were ampliﬁed in a Gene Amp PCR system 9700 (Applied
Biosystems, Rotkreuz, Switzerland) thermal cycler using
the following temperature proﬁle: denaturation, 94 ◦C, 30 s
(ﬁrst cycle 2min at 94 ◦C); annealing, 52 ◦C, 30 s; extension,
72 ◦C, 3min. Following 40 cycles, a ﬁnal extension step was
added for 5min at 72 ◦C. PCR products were then subcloned
into the pET 151/D-TOPO vector (Invitrogen, Carlsbad, CA,
USA; cat. no. K 151-01), using the polylinker of the vec-
tor designed to produce proteins with an N-terminal 6×
His tag. The recombinant vector was used to transform
E. coli one-shot TOPO10 chemically competent cells. Trans-
formants were selected on LB agar plates containing
100g/ml ampicillin after overnight culture at 37 ◦C.
2.4. Colony PCR
Colony PCR was used to check whether a speciﬁc colony
had the desired recombinant plasmid. Small colonies were
suspended in 50l H2O, heated for 5min at 95 ◦C and
then ampliﬁed by PCR as follows. PCR was performed in a
100l reaction volume using 1l colony suspension, con-
taining 1× PCR buffer (1.5mmol/l MgCl2), 1 pmole of each
primer (T7 forward primer/insert reverse primer or insert
forward/T7reverse), 0.1mmol/l dNTP mix and 2.5U Taq
polymerase. Samples were ampliﬁed in a thermal cycler
using the following temperature proﬁle: denaturation, 94 ◦C
(ﬁrst cycle 2min at 94 ◦C) 30 s; annealing 55 ◦C, 30 s; exten-
sion, 72 ◦C, 1min, 30 s. Following 40 cycles, a ﬁnal extension
step was added for 5min at 72 ◦C.
2.5. Expression and puriﬁcation of recP29
Positive clones picked from LB agar plates were cultured in
5ml LB medium with 100g/l ampicillin and subjected for
plasmid extraction using the Plasmid Miniprep Kit (peQLab,
Erlangen, Germany). Plasmids were then transfected into E.
coli BL 21 (DE3), chemically competent cells, and incubated
in 250l SOC medium with shaking for 40min at 37 ◦C,
followed by overnight cultivation at 37 ◦C on LB amp agar
plates. Two hundred microlitres of overnight culture was
inoculated into a new LB medium containing the appropriate
antibiotic, then submitted to mass production using 5ml
overnight culture inoculated into 200ml LB amp medium
with 2 h incubation and shaking at 37 ◦C until an optical den-
c
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ity of 0.5—0.8 was reached. Isopropyl--D-thiogalactoside
IPTG; Sigma, Buchs, Switzerland) was subsequently added
o a ﬁnal concentration of 1mmol/l. Expressed recombi-
ant protein was extracted from bacterial cells using Triton
-100 buffer followed by four sonications of 30 s at 57W
n a soniﬁer cell disruptor B-12 (Bransonic Power Company,
anbury, CT, USA), and subsequently analysed for its
olubility. After centrifugation (14 000 g for 10min at 4 ◦C),
he clariﬁed supernatant was loaded into a cobalt-based
esin column (TALON HIS-Tag Puriﬁcation resin; BD Bio-
ciences, Allschwil, Switzerland) to capture the His-tagged
ecombinant protein. After three times washing with PBS
0mmol/l, 5mmol/l imidazole pH 7.0, the recombinant
usion protein was eluted using buffered imidazole at
50mmol/l. Eluted protein was dialyzed overnight against
BS and stored at −20 ◦C until used. Protein expression and
uriﬁcation were checked by SDS-PAGE and Coomassie Blue
-250 staining. Protein concentration was determined using
he Bio-Rad-Bradford protein assay (Bio-Rad Laboratories
G, Reinach, Switzerland; cat. no. 500-0002) with bovine
lasma immunoglobulin as standard.
.6. Sera from CE patients
n total, 290 sera were collected from 54 patients aged
etween 3 and 15 years (Table 2). All cases were surgi-
ally, radiologically and/or histologically proven. For each
ase, a ﬁrst serum specimen was obtained at the time of
iagnosis (before medical intervention) and further samples
uring a follow-up period ranging between 7 d and 5 years
ost-surgery and/or chemotherapy. The intervals and num-
ers of follow-up steps were variable between the patients,
nd the mean serum sample number per patient was 7± 2.
asically, sera were the same as those used in our two pre-
ious investigations,10,23 thus allowing a direct comparative
ssessment. Brieﬂy, the follow-up design was as follows: sub-
equent to the initial diagnostic investigation, each patient
as subjected to both serology and imaging investigation
week after surgery and/or chemotherapy, and then after
month, after 6 months and once the following year.
ydatid cysts were classiﬁed into ﬁve types according to
HO26 classiﬁcation: type CE 1 (unilocular, simple cysts);
ype CE 2 (multivesicular, multiseptated cysts); type CE 3
uniloclar cysts, which may contain daughter cysts); type
E 4 (heterogeneous or hyperechoic degenerative contents);
nd type CE 5 (calciﬁed cysts). Types CE1 and CE 2 rep-
esent the active and progressive phase of CE; type CE 3
epresents the transitional stage, during which it usually
tarts to degenerate; and types CE 4 and CE 5 represent
he inactive and regressive phase. Depending on imaging
ndings at the endpoint of follow-up and on the respec-
ive surgeon’s classiﬁcation, 54 patients were clustered into
wo different groups: group A included cured or inactive
ydatid disease cases (CCE; n = 40/54), in which the hydatid
yst had disappeared following surgery or had fully calci-
ed in ﬁve cases (type CE 5); the other cases remainedal symptoms, size and shape of remaining lesions. Group
included patients who presented still active CE (NCCE;
= 14/54) and/or a progressive form of disease after obvi-
usly unsuccessful (non-complete) surgical removal of the
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Table 2 Overview of the clinical features of the two groups of young cystic echinococcosisa patients included in the present study.
nb Sex Mean age (range)
in years
Cyst localization and typec Therapy and follow-upe
F M Lungs Liver Multipled nf Period
(months)
Surgery
only
ABZ
only
Surgery
plus ABZ
Years
(mean± SD)
CCE 40 16 24 9 (3—15) 18 CE1
(18)
11 CE1 (5) 11 CE1 (9) 6 2—48 34 0 6 3± 2
CE2 (2) CE2
(2)CE3 (3)
CE4 (1)
NCCE14 4 10 9 (4—14) 5 CE1
(5)
6 CE1 (2) 3 CE1 (2) 9 12—60 5 2 7 3± 2
CE2 (2) CE3
(1)CE3 (2)
a Cured cystic echinococcosis (CCE) and non-cured cystic echinococcosis (NCCE) patients.
b Total number of patients.
c Cyst type (CE1 to CE4; no CE5) corresponds to the sonographic classiﬁcation carried out at initial diagnosis, according to WHO26.
d Multiple locations indicate that cysts were detected in the liver and the lungs (10 cases), the liver and spleen (one case), the liver and mediastinum (one case) or the liver, lungs and
heart (two cases).
e For CCE patients, chemotherapy [albendazole (ABZ)] was added to surgery when cysts were considered as ﬁssured. In NCCE patients, ABZ was administered in cases exhibiting ﬁssured
cysts, multiple cysts and disseminated or inoperable cysts left after surgery. Cysts were considered to be ﬁssured when the laminated layer and consequently germinal layer presented
visible damages that no longer maintained the original healthy status of hydatid cysts. If respective cysts were punctured, the hydatid ﬂuid appeared milky or coloured, and high protein
concentrations (i.e. ≥1mg protein/ml) were resolved.
f Number of patients who received chemotherapy (ABZ), alone or combined with surgery.
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TRecombinant Echinococcus granulosus P29 serology
cyst(s), or for whom surgery was not feasible (type CE 1, CE
2 and CE 3; for more details see Ben Nouir et al.10,23).
Sera were tested by ELISA and immunoblotting altogether
in one run in order to avoid temporally related inter-test
variations.
2.7. SDS polyacrylamide gel electrophoresis
(SDS-PAGE) and immunoblotting
Recombinant P29 protein was solubilized with SDS sample
buffer (1mol/l Tris HCl, pH 6.8 containing 2% SDS, 5%
2--mercaptoethanol and 10% glycerol) at 100 ◦C for 5min
and electrophoretically separated in a 15% polyacrylamide
gel. Recombinant protein was loaded at a concentration
of 0.2g/cm slot of the preparative gel. HCF was elec-
trophoresed as previously described.10 Electrophoretically
resolved molecules were transferred onto nitrocellulose
(MB 85) and then cut into strips of 3mm width. Strips were
subsequently incubated with sera diluted 1/100 in PBS
plus 5% skimmed milk and 0.3 % Tween 20. Incubation was
overnight at 4 ◦C. Strips were then washed and incubated
with goat anti-human IgG horseradish peroxidase conjugate
diluted 1/400 (Sigma A6029) for 2 h at room temperature.
Colour reaction was developed using the chromogenic
substrate 3,3′-diaminobenzidine tetrahydrochloride (DAB)
and 0.03‰ H2O2.
2.8. ELISA
Nunc Immulon ELISA microplate strips were coated by
overnight incubation at 4 ◦C with 50l per well of either
recombinant protein (1.0g/ml), or HCF (10.0g/ml)
diluted in ELISA coating buffer (0.1mol/l NaHCO3/Na2CO3
pH 9.6, and containing 0.02% NaN3). The wells were then
washed three times with washing buffer (PBS, 3% Tween
20) and subsequently blocked with blocking buffer, consist-
ing of PBS (pH 7.2) containing 0.05% bovine haemoglobin
and 0.02% NaN3. Sera were diluted 1:100 in blocking buffer,
and phosphatase alkaline-labelled anti-human IgG conjugate
(Sigma, A 5403) was used at a 1:2500 dilution. All incuba-
tions were carried out at 37 ◦C for 30min. Plates were ﬁnally
washed four times. After incubation with the substrate for
15min, the reaction was stopped with 10l 3N NaOH. The
absorbances (A405 nm) were read with a microplate reader
(Dynex Technologies BioConcept, Allschwil, Switzerland)
and the results expressed in arbitrarily deﬁned antibody
units (AU) as previously described.27
2.9. Statistical analyses
Student’s t test was used to calculate the 2 performance
for comparing seropositivity between each group of patients
with each type of antigen. A P-value of ≤0.05 was considered
statistically signiﬁcant.
3. Results3.1. MS-MS analysis and database search
The resulting peptide fragments from each excised band
of 27 and 28 kDa were individually subjected to database
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esearch homology using the Mascot research engine. On the
ne hand, overlapping fragment sequences resulting from
he 27 kDa band revealed 51% sequence coverage of amino
cid sequences corresponding to the P29 E. granulosus pro-
ein (SwissProt accession no. Q9U8G7), and 10% sequence
overage of that corresponding to Taenia solium triosephos-
hate isomerase protein (SwissProt accession no. Q9GTX8).
hese proteins were identiﬁed with high conﬁdence. On the
ther hand, overlapping peptide fragments resulting from
he 28 kDa band showed 11% coverage sequence of actin
mino acid sequence of T. solium (SwissProt accession no.
68555), with low conﬁdence, and 37% sequence coverage
f the 14-3-3 homologue two amino acid sequence of E. gran-
losus (SwissProt accession no. Q8MUA4) and 23% of that
f the putative 14-3-3 protein of E. granulosus (SwissProt
ccession no. Q56J98).
Based on these ﬁndings and our previous experiences
ith E. multilocularis 14-3-328 and a publication on P29,29
e decided to carry on further experiments only with P29.
29 is a metacestode-speciﬁc component of E. granulosus29
ith a corresponding amino acid sequence predicted from
he open reading frame composed of 238 residues, with a
educed molecular mass of 27 097Da and a predicted iso-
lectric point of 5.6. This protein contains 1 BAR domain
rom position 18 to 238 amino acids and does not contain
signal peptide cleavage site (signal P 3.0). The deduced
29 sequence contains 19 sites for potential serine (10),
hreonine (6) and tyrosine (3) phosphorylations (NetPhos
.0) and two sites for potential asparagine-threonine N-
lycosylations (NetNglyc1.0), in addition to four sites for
otential serine-threonine N acetylation (Yin OYang 1.2).
Homology searches in the SwissProt database using the
uick Blast P engine showed that P29 has a full identity to the
ntigen ‘S’ epitope (Fragment) of Echinococcus granulosus30
nd 97% identity to antigen 6 (Fragment) [Adama6] of
chinococcus multilocularis.31 Alignments of P29 with these
omologous proteins are shown in Figure 1.
.2. Cloning, expression and puriﬁcation of P29
29-ampliﬁed cDNA was directly inserted into the pET 151
/expression vector for the subsequent transformation of
OP 10 chemically competent E. coli. The cloning was veri-
ed by colony PCR. Among 10 selected positive colonies, six
ere shown to contain the plasmid with inserts in the correct
rientation. The plasmids of one selected positive clone (no.
) were transferred into the E. coli BL21 strain for expres-
ion. Expressed proteins were subsequently puriﬁed from
acterial lysate by afﬁnity-puriﬁed cobalt chromatography,
hen identiﬁed on a 15% Coomassie Blue-stained SDS-PAGE
el run under reducing conditions. The puriﬁed protein was
tored at −20 ◦C until used for subsequent serological tests.
.3. Follow-up characteristics of recP29 ELISA
he serological follow-up of patients from CCE and NCCE
atients is shown in Figure 2. Among 40 CCE patients tested,
5 (38%) showed no detectable anti-recP29 antibodies at
he initial time of diagnosis, nor during the whole period
f follow-up. The other 25 patients all showed anti-recP29
ntibody response at different time points of follow-up.
360 N.B. Nouir et al.
Figure 1 Alignment (MultAlin at the Institut National de Recherche Agronomique, Paris, France) of the deduced amino acid
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3equence of P29 (SwissProt accession no. Q9U8G7) with homolo
osus (SwissProt accession no. Q7JPY7) and antigen 6 (Fragmen
eptides identiﬁed by MS/MS are underlined.
n general, a progressive decrease of respective antibody
evels during the timecourse of follow-up was observed.
ore precisely, at time of diagnosis (D0; before surgery),
2% of these patients exhibited a low but positive anti-
ody level (AU <20), while the remaining, 30% patients had
o detectable anti-recP29 antibodies. Conversely, anti-HCF
ntibodies were initially detected in 86% of the patients,
ith generally high levels (AU 85-185). With regard to com-
aring hepatic versus pulmonary cyst localization, initial
eronegativity by recP29 ELISA was seen in 12 out of 18 lung
CE cases and in all ﬁve lung NCCE cases, while two out
f 11 liver CCE cases and two out of six liver NCCE cases
ere seronegative at the entrance into the study. Thus, the
eronegativity rate was higher for lung localizations than
or the liver. The post-treatment evolution of anti-recP29
a
l
a
Table 3 Comparison of percentage seropositivity as determined b
CCE and 11 non-cured cystic echinococcosis (NCCE) patients during
D0 D7 1M
CCE (n = 22) (n = 19) (n =
recP29 ELISA-positive (%) 7 (32) 15 (79) 18 (
HCF ELISA-positive (%) 19 (86) 15 (79) 20 (
NCCE (n = 10) (n = 7) (n =
recP29 ELISA-positive (%) 3 (30) 5 (71.4) 7 (8
HCF ELISA-positive (%) 8 (80) 7 (100) 8 (1
a Serum samples were collected before surgery (D0) and 1 week (D7),
more years (≥3Y) after surgery. Statistically signiﬁcant differences betproteins: antigen S epitope (Fragment) of Echinococcus granu-
dama6] of E. multilocularis (SwissProt accession no. Q24901).
ntibody levels showed that in 80% of CCE patients (20 of
5 CCE cases), immunoglobulin levels increased during the
rst 1—6 months after surgery (including also those patients
ho were initially seronegative before treatment but who
ecame seropositive after treatment), reaching their high-
st level at 1 month post-operation. Subsequently, levels
tarted to progressively decrease, and anti-recP29 antibod-
es were detectable in only 15 and 11% at 1 and 2 years
ost-operation, respectively. Interestingly, no CCE patient
howed any further anti-recP29 antibody reactivity past
years post-surgery, compared with 89% when using HCFs antigen (Table 3).
In general, recP29 ELISA showed a faster decrease of IgG
evels than the HCF ELISA, and seronegativity was reached in
ll CCE patients (100%) at the endpoint of follow-up of each
y recP29 ELISA and HCF ELISA in 25 cured cystic echinococcosis
their follow-up perioda.
6M 1Y 2Y ≥3Y
22) (n = 21) (n = 20) (n = 18) (n = 19)
82) 6 (29) 3 (15) 2 (11) 0 (0)
91) 20 (95) 18 (90) 18 (100) 17 (89)
8) (n = 10) (n = 10) (n = 6) (n = 10)
7.5) 8 (80) 7 (70) 5 (83.3) 7 (70)
00) 9 (90) 9 (90) 6 (100) 10 (100)
1 month (1M), 6 months (6M), 1 year (1Y), 2 years (2Y) and 3 or
ween both clinical groups was noticed in recP29 ELISA (P < 0.05).
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Figure 2 Post-treatment evolution of antibody levels
expressed as antibody units (AU), determined by ELISA in
29 cured cystic echinococcosis (A) and 11 non-cured cystic
echinococcosis (B) patients. Serum samples were collected
patient was clinically considered to have still active cysts
with small daughter vesicles. Overall, 10 out of 11 NCCE
(91%) patients remained positive at the endpoint of follow-
up (1—5 years post-surgery). HCF ELISA with NCCE patients
exhibited higher antibody levels as well as higher rates of
seropositivity than recP29 ELISA at diagnosis and during the
whole follow-up period. None of the patients became neg-
ative at the endpoint of follow-up. A comparative analysis
of sensitivities regarding recP29 and HCF in CCE and NCCE
patients is shown in Table 3.
3.4. Follow-up characteristics of recP29
immunoblot
The same cohort of follow-up sera collected from CCE
and NCCE patients were also tested by immunoblotting
for their immunoreactivity to recP29 (Figures 3 and 4). Of
40 CCE patients, 11 (28%) were serologically negative to
recP29 at D0 and during the whole period of follow-up; the
remaining 29 patients were immunoreactive to the recom-
binant protein. With regard to comparing hepatic versus
pulmonary cyst localization, initial seronegativity by recP29
immunoblot was seen in nine out of 18 lung CCE cases and
three out of ﬁve lung NCCE cases, while one out of 11 liver
CCE cases and three out of six liver NCCE cases were seroneg-
ative at the entrance into the study. Thus, the seronegativity
rate was higher for lung localizations than for the liver.
These 29 patients immunoreactive to recP29 (including also
Figure 3 Comparison of temporal evolution between recP29
band (white) recognition and hydatid cyst ﬂuid (AgB) (black)
by immunoblotting in 29 cured cystic echinococcosis (A) and 11
non-cured cystic echinococcosis (B) patients upon timecourse
after treatment. Serum samples were collected before surgery
(D0) and 1 week (D7), 1month (1M), 6 months (6M), 1 year (1Y)before surgery (D0) and 1 week (D7), 1 month (1M), 6 months
(6M), 1 year (1Y), 2 years (2Y) and 3 or more years (≥3Y) after
surgery.
patient (which ranged between 1 and 5 years post-surgery),
compared with only 10% as determined with the HCF ELISA.
Some sera were followed-up for another few years, although
seronegativity had already been reached at 1, 2 and 3 years
after treatment. However, recP29 ELISA of 14 patients with
still-active CE (NCCE) showed that three of them (21%) had
no detectable anti-recP29 antibodies at time of diagnosis
(D0) and also during the whole period of follow-up. At D0
(before surgery), 30% from the remaining 11 patients who
were initially positive (with generally low antibody levels
of AU <24) reached an increasing maximum level at 1 month
post-surgery (Table 3). Subsequently, a progressive decrease
but without seronegativity at the endpoint of follow-up was
observed, except for one patient, who became seronega-
tive within 3 years after surgery and remained negative
for the subsequent 4 and 5 years after surgery, while the
and 3 or more years (≥3Y) after surgery. Statistically signiﬁ-
cant differences between the two clinical groups was observed
with both recP29 immunoblotting and HCF immunoblotting
(P = 0.012; P = 0.005).
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Figure 4 Representative examples of immunoblotting proﬁles using recP29 as antigen, and shown with an example of ﬁve cured
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week (D7), 1 month (1M), 6 months (6M), 1 year (1Y), 2 year
hose patients who were initially seronegative before treat-
ent but who became seropositive after treatment) showed
n interesting progressive decrease of anti-recP29 banding
ntensity. This effect was mostly noticed at 6 months post-
urgery, when the protein was recognized in 40% of patients
detectability rate among 29 patients). At later time points,
eropositivity sharply decreased to 7% over 3 years post-
reatment, compared to 29% in HCF immunoblot (Figure 3A).
ll patients (n = 29) converted to negative at their respective
ndpoint of follow-up except two, who remained positive at
and 2 years post-surgery, respectively. Nevertheless, all
f them were negative by recP29 ELISA but remained still
ositive in the HCF ELISA.
Thus, the overall immunoblot negativity at the endpoint
f the follow-up period was documented in 27 out of 29
atients (93%), compared with 72% (21 out of 29 patients)
btained by HCF immunoblot. In general, CCE patients
xhibited a faster progressive decrease of immunoreac-
ivity as well as higher rate of seronegativity to recP29
n immunoblotting than observed with HCF immunoblot
antibody reactivity to AgB fractions). A direct comparison
etween seroreactivities to both antigens is shown in
igure 3A. Conversely, all 14 NCCE patients showed a
tronger recognition of recP29, which persisted for years
ost-surgery until the endpoint of follow-up, except one
CCE patient, who showed a weak anti-recP29 reactivity
t 3, 4 and 5 years post-treatment. This patient converted
lso to negative in the recP29 ELISA. Overall, recP29 was
ersistently recognized in 13 out of 14 NCCE patients (93%)
ver 3 years post-surgery, compared with 100% when tested
ith HCF (AgB) immunoblotting. Statistically signiﬁcant
a
d
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p
vB) patients whose sera were collected before surgery (D0) and
), 3 years (3Y) and 4 years (4Y) after surgery.
ifferences between CCE and NCCE patients were noticed
n both recP29 ELISA and recP29 immunoblotting (P = 0.029,
= 0.012) and with HCF-immunoblotting (P = 0.005).
A comparison between CCE patients that obtained either
urgical treatment alone or surgery plus albendazole (ABZ)
herapy showed no difference at the descriptive level (the
atients’ numbers being too small to allow a proper sta-
istical analysis). The same holds true for the comparison
etween NCCE patients with either surgery alone, ABZ alone
r surgery plus ABZ, where no differences became appar-
nt (data not shown). More patients need to be respectively
nvestigated in order to reach statistical signiﬁcance for such
nalyses.
. Discussion
wo native E. granulosus protoscolex-speciﬁc ‘bands’ identi-
ed in a previous study23 were subjected to MS/MS analysis,
ielding high sequence homologies with either the P29
rotein29 or the 14-3-3 isoform 2 of E. granulosus.32 Based
n the biology of 14-3-3, we did not see any reason to
nclude this antigen as a potential candidate for the present
erological follow-up study. Conversely, the P29 protein ﬁrst
escribed by Gonzalez et al.29 appeared interesting by its
xpression being restricted to E. granulosus protoscoleces33nd by exhibiting a good immunodiagnostic potential to
etect CE in patients before surgery.29 Our investigations
ow showed that a recombinant P29 also exhibits a good
rognostic value in the follow-up monitoring of those cured
ersus non-cured CE patients who were able to develop a
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seropositive status against recP29 either before or shortly
after diagnosis and/or initiation of a treatment protocol,
respectively. A certain portion of CE patients remained con-
stantly negative against recP29 from day 0 (before surgery)
until the endpoint of the present follow-up (38% CCE and 21%
of NCCE patients for ELISA, and 27% of CCE patients only
for immunoblotting). This could be related to the obser-
vation that most of these anti-recP29-negative patients
presented lung cysts. It is commonly known that lung cysts
do not yield an intense humoral response due to sepa-
ration of the cysts from the surrounding pulmonal tissue
and therefore weak release of parasite metabolites (anti-
gens) into the pulmonal circulation, resulting in a poor host
immune response. In addition, lung cysts are frequently
sterile; therefore even after a putative rupture or other-
wise exposure to cyst content, there would have been no
protoscolex-dependent antigenic challenge. As P29 appears
restricted, in its expression, to protoscoleces, this would
then result in a lack of P29-stimulation and consequently
in a respective seronegativity. Moreover, some of the CE
patients who were seronegative to recP29 at D0 (before
surgical intervention) seroconverted after treatment and
demonstrated increasing anti-recP29 antibody levels during
the ﬁrst 6 months after surgery. This may have indicated
a post-operative protoscolex-exposure; in that case, anti-
recP29 serology may be of interesting prognostic value in
the follow-up of CE patients. When comparing recP29 by
ELISA and immunoblotting, it became evident that ELISA
showed a lower diagnostic and post-operative sensitivity
than immunoblotting, especially also in the frame of long-
term follow-up assessments. Anti-recP29 seronegativity was
reached more quickly by ELISA than by immunoblotting, i.e.
all initially anti-recP29-reactive CCE patients had negative
ELISA results at latest by 3 years post-surgery. A possible
reason for this may be the structural difference of the anti-
gen, as in ELISA the recombinant protein remains more or
less native, with some of the conformational epitopes being
kept obscured. In immunoblotting, however, most proteins
become linearized and thus potentially hide epitopes for
respective antibody-binding capacities.
We also directly compared the prognostic value of the
recP29 antigen with that of native HCF. In the recP29 ELISA,
seronegativity in CCE patients was reached much faster than
in HCF ELISA. While all CCE patients who initially had an anti-
recP29 seropositivity became anti-recP29-negative within
3 years after surgery, 86% of corresponding CCE patients
were still HCF-ELISA-positive more than 3 years after oper-
ation. Furthermore, HCF ELISA did not allow the detection
of differences in the post-operative antibody level devel-
opment between CCE and NCCE patients (differences were
statistically not signiﬁcant; P > 0.05).
Li et al.16 reported a recombinant protein (termed
‘EpC1’) that was expressed from a protoscolex cDNA library.
They showed a slightly higher (92%) sensitivity than that
obtained with HCF at D0 (before surgery). By contrast to
our recP29, however, EpC1 immunoblotting did not decrease
during follow-up after treatment and was still high (92%)
even with sera obtained 6 years after surgery.
Sequence analyses showed that the P29 gene presents
97% homology to the sequence of Antigen 6 (fragment Adama
6) of E. multilocularis.31 Therefore, we can assume that sera
from E. multilocularis patients may exhibit a cross-reactive363
otential with recP29, and we will address this point in
uture investigations.
P29 also showed full identity (100%) with the Anti-
en ‘S’ epitope (Fragment) of E. granulosus30 at the
mino acid level. The Ag ‘S’ epitope (152 amino acids)
as characterized as an immunogenic epitope responsi-
le for precipitation of ‘arc 5’ in immunoelectrophoresis.34
mmunological and proteomic analyses by peptide ﬁnger-
rinting on the Ag5 and P29 relationship showed that P29 and
g5 are immunologically related but are distinct proteins.29
hamekh et al.22 reported a synthetic peptide of 34 amino
cids, designated 89—120, which mimics an epitope of Ag5;
his peptide showed a high diagnostic performance with
egard to sensitivity and speciﬁcity.35 This peptide corre-
ponds also to the region involved in cross-reactivity with
29 (residues 144—177 of P29) with Ag 5.29 We suggest that
ore work needs to be done to further elucidate the biolog-
cal and genetic relationship between antigen 6, antigen 5
nd P29.
In conclusion, we have successfully cloned and expressed
he gene encoding for P29, a protoscolex-speciﬁc compo-
ent of E. granulosus. Our preliminary results showed that
ecP29 demonstrated a very good performance as an antigen
arker for the serological follow-up of human CE in those
atients who were capable of mounting an anti-recP29 anti-
ody response either before shortly after diagnosis and/or
nitiation of treatment. We suggest that recP29 serology
hould be more intensively tested with CE follow-up cases of
ther ages and other geographical areas in order to provide
more extensive documentation of the prognostic capacity
f this tool.
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